key: cord-0764460-3hg050qh
authors: Bharti, Reena; Srivastava, Ashish; Roy, Trisha; Verma, Khushboo; Reddy, DV Siva; Shafi, Hasham; Verma, Sonia; Raman, Sunil K.; Singh, Amit K.; Singh, Jyotsna; Ray, Lipika; Misra, Amit
title: Transient transfection of the respiratory epithelium with gamma interferon for host-directed therapy in pulmonary tuberculosis
date: 2020-10-22
journal: Mol Ther Nucleic Acids
DOI: 10.1016/j.omtn.2020.10.023
sha: deacedde3db4b04c34982e1973f50c0d7b2a0055
doc_id: 764460
cord_uid: 3hg050qh

Nebulized gamma interferon (IFN-γ) protein has been studied for clinical safety and efficacy against pulmonary tuberculosis (TB). The protein is expensive, requires a cold chain, and is difficult to deploy in limited-resource, high-incidence settings. We generated preclinical proof of concept (PoC) for a dry powder inhalation (DPI) containing DNA constructs to transiently transfect the lung and airway epithelium of mice with murine IFN-γ. Bacterial colony forming units (CFU) in the lungs of mice infected with Mycobacterium tuberculosis (Mtb) reduced from about 106/g of tissue to ∼104 after four doses given once a week. Nodular inflammatory lesions in the lungs reduced significantly in number. Immunohistochemistry of infected lung sections for LC3-1 and LAMP-1 indicated autophagy induction between 18-48h after inhalation. ELISA on bronchioalveolar lavage (BAL) fluid showed differences in kinetics of IFN-γ concentrations in the epithelial lining fluid of healthy versus infected mice. Uninfected mice receiving DNA constructs expressing a fluorescent protein were live-imaged. The fluorescence signals from the intracellular protein peaked at about 36h after inhalation and declined by 48h. These results establish preclinical PoC of the efficacy of a DPI and dosing regimen as host-directed and transient gene therapy of experimental pulmonary TB in mice, justifying preclinical development.

inhalation of IFN-γ provided healing effects rather than inflammatory pathology in patients of 67 pulmonary TB. IFN-γ is known, among other host defense functions, to induce autophagy in 68 cells infected with the intracellular pathogen Chlamydia. 19 Our group has also observed that the 69 lung architecture of Mtb-infected mice improves significantly upon pulmonary delivery of drugs 70 that induce autophagy. 20, 21 We therefore hypothesized that intermittent exposure to IFN-γ would 71 drive a host defense program against the pathogen that would include induction of autophagy, 72 without inducing immunopathology. A DPI formulation for transient transfection of the airways 73 and deep lungs was prepared and evaluated to test these hypotheses and provide preclinical proof 74 of concept (PoC) for IFN-γ HDT using species-autologous gene delivery. 75 

Bacterial burden and lung pathology 77 We infected 36 mice by the aerosol route with a low dose of Mycobacterium tuberculosis 78 (Mtb) and started treatment with once-weekly inhalations 28 days later (Fig. 1A) . The mice were 79 made to inhale about 100 µg of a dry powder containing about 5 ng of plasmid bearing the 80 J o u r n a l P r e -p r o o f mouse gene for IFN-γ (Ifng) by nose-only exposure. 22 The initial inoculum of bacteria received 81 by the mice was about 100 colony forming units (CFU) per gram of lung tissue as shown in Fig.   82 1B. The CFU/g grew to about a million in the lungs; and ten thousand in the spleen by the time 83 treatment was started. At the end of the fourth week, no culturable bacteria were found in the 84 lungs of one of the two mice receiving once-weekly inhalations. In a two-sample t-test of actual 85 power 0.99 at alpha 0.05, the mean lung CFU/g after four weeks of treatment group was 86 significantly different from the untreated mice. The CFU counts in the spleen were apparently 87 reduced on treatment, but were not significantly different between treated and untreated animals 88 (Fig. S1 ). 89 Fig. 2 shows the lungs of the mice after they had received one, two, three, or four doses 90 of the DPI. There was progressive improvement in the gross organ pathology and reduction in 91 the number of visible nodular lesions. If the mice received no treatment, severe pathology was 92 evident at 56 days post-infection (Fig. 2E ). 93 Autophagy in lung tissue 94 Lung sections of mice infected with Mtb 28 days prior to receiving a single inhaled dose 95 (100µg DPI, 5ng plasmid) were stained for markers of autophagy. Fig. 3 shows that LC3-II and 96 LAMP-1 expression was low in animals that received no treatment, and in treated animals 97 examined at 7h after inhalation. After 18h, expression of these markers increased discernibly. 98 The two markers co-localized extensively at 48h post inhalation. were markedly different. The time (t max ) taken to attain maximal concentrations (C max ) differed 126 strongly between uninfected (~8h) and infected mice (~30h) on account of a lag-time (T lag ) of 127 nearly 18h in the latter case. We note a correspondence between the pharmacodynamic outcome 128 of induction of autophagy (Fig. 3 ) starting at about 18h and the T lag calculated here (Table S1) . 129 The C max in BAL fluid was nearly 3-fold higher in infected animals. A one-compartment 130 pharmacokinetic model with a time lag following extravascular administration was fitted to the 131 data using PK Solver 2.0 23 . The values of other calculated pharmacokinetic parameters are given 132 in Table S1 . (Table S2) . Because a solution has uniform composition 203 throughout its bulk, "uniformity of content" in the product is assured. We also routinely establish in the same animal's spleen (Fig. 1B, S2 ) and residual nodular lesions in the lungs (Fig. 2D ) 216 J o u r n a l P r e -p r o o f assures us that it received the initial inoculum, but ambiguity remains whether the animal's lungs 217 were significantly colonized to begin with. Transfection of only one lung (Fig. 6G ) points out 218 that it is possible that the mouse that had no bacteria in the lungs received a smaller initial 219 inoculum. Next, IFN-γ is intended as adjunct HDT, and not as a stand-alone intervention. to be studied in a model such as the guinea pig or non-human primate to evaluate efficacy 231 against a mix of bacterial populations residing inside or outside host cells. Finally, we used the 232 mouse cytokine gene rather than the human gene in these experiments, so it might be argued that 233 our results would not apply to human IFN-γ. However, it is only logical to use the species-234 autologous gene in order to express a protein that will be treated as "self" by the host immune 235 system. 236 With these caveats, we submit that we establish preclinical PoC of non-viral, transient 

A phase i trial of recombinant gamma 331 interferon in patients with cancer

A randomized phase i/ii study of continuous versus 334 intermittent intravenous interferon gamma in patients with metastatic melanoma

Lack of a therapeutic role for interferon γ in patients with 351 tuberculosis

Frequency and type of reactions to 353 antituberculosis drugs: Observations in routine treatment

Host directed therapies for tuberculosis: Futures 355 strategies for an ancient disease

Host-directed therapies for tuberculosis

Host-directed therapies and holistic 360 care for tuberculosis

Progress in tuberculosis vaccine development and host-363 directed therapies-a state of the art review

Inhalable particles containing rapamycin for induction of autophagy in macrophages 366 infected with mycobacterium tuberculosis

Opportunities and challenges for host-directed therapies in tuberculosis

Interferon gamma-1b therapy for cryptogenic fibrosing alveolitis

Fluorescent reconstitution on 417 deposition of pm(2.5) in lung and extrapulmonary organs

Animal models of tuberculosis: Lesson learnt

Small-scale gmp production of plasmid 423 DNA using a simplified and fully disposable production method

None of the authors has any conflict of interest to disclose.